A data-driven strategy can assess the quality of legacy drugs developed before 2011 process-validation requirements were established.
Robert Rhoades
Advertisement
Robert Rhoades is managing partner at Validant.
Articles by Robert Rhoades
Advertisement
Latest Updated Articles
Assessing Legacy Drug QualityPublished: July 2nd 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
2
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
3
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
4
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
5
